RBC Capital Upgrades Dynavax Technologies (DVAX) to Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to RBC Capital Upgrades Dynavax Technologies (DVAX) to Outperform

Dynavax (DVAX) Doubles Early on FDA Panel Backing

July 31, 2017 6:58 AM EDT

Dynavax (NASDAQ: DVAX) shares are trading up 105% in pre-open trade following FDA panel backing for HEPLISAV-B for hepatitis B.

... More

JPMorgan Upgrades Dynavax Technologies (DVAX) to Overweight, Negatively Revises EPS Estimates

July 31, 2017 4:45 AM EDT

JPMorgan upgraded Dynavax Technologies (NASDAQ: DVAX) from Neutral to Overweight with a price target of $27.00 (from $6.00).

Analyst Anupam Rama believes Heplisav has a high probability of a approval come August 10th PDUFA. Rama further comments about the under-appreciated SD-101 asset "we believe... More